FLC
MRVI icon

Fifth Lane Capital’s Maravai LifeSciences MRVI Stock Holding History

Fifth Lane Capital’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,000
Closed -$100K – 153
2023
Q3 		$100K Buy
+10,000
New +$110K 0.03% 120

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Fifth Lane Capital's MRVI Position: Q4 2023 in Review

Fifth Lane Capital sold out of Maravai LifeSciences (MRVI) in Q4 2023, closing a stake of 85,000 shares — an estimated $935K sold.

Fifth Lane Capital first reported a position in MRVI in Q2 2023 and held it in 2 quarters. The position peaked at $935K in Q3 2023. 223 funds tracked by Wall St. Rank hold MRVI as of Q4 2023.

  • Fifth Lane Capital reported no remaining Maravai LifeSciences position as of Q4 2023 after selling out during the quarter.
  • Fifth Lane Capital sold 85,000 Maravai LifeSciences shares in Q4 2023, an estimated $935K.
  • Fifth Lane Capital first reported a position in Maravai LifeSciences in Q2 2023 and held it in 2 quarters.
  • Fifth Lane Capital's Maravai LifeSciences position peaked at $935K in Q3 2023.
  • 223 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2023.

Based on Fifth Lane Capital's 13F filing for Q4 2023, filed 14 Feb 2024.